Challenges and Opportunities in Characterizing the Genetics of Stuttering: From Sample Acquisition to Functional Interpretation of the Genome.

This is a review of genetic studies, not a clinical trial, so it does not test any therapy or patient outcome. Genome-wide associations identify statistical links, not causes, and many variants are expected to have small effects. Case definitions varied across clinical assessment, survey self-report, parent report, and predicted electronic health record phenotypes, each with different accuracy. Large genetic databases still undercapture stuttering, and many analyses have historically focused on European ancestry, which limits generalizability. The new transcriptome-wide results are computational predictions and need laboratory and clinical validation.

Funding declarations list NIH/NIDCD support, BioVU control sample support, and NCATS awards. The authors also describe a data partnership with 23andMe through its Research Innovation Collaborations Program. No explicit author conflict-of-interest disclosures are provided.

Do not conclude that a genetic test can diagnose, subtype, or treat stuttering. The paper reports associations and methodological challenges, not causal proof or clinical utility.